ADVANCED CANCER THERAPEUTICS

Advanced Cancer Therapeutics, LLC engages in the discovery, development, manufacture, and commercialization of cancer therapeutics. It develops a pipeline of anti-cancer products, including MIF, a macrophage migration inhibitory factor; PU27, a synthetic oligonucleotide that is used as an anticancer compound; PFKFB3, a small molecule compound; CK37, a small molecule that inhibits cell proliferation, choline kinase enzymatic activity, and tumor growth; and a vaccine for human papilloma virus, which is caused for cervical cancer. The company was founded in 2007 and is based in Louisville, Kentucky.